Elocalcitol

Drug Profile

Elocalcitol

Alternative Names: BXL 628; Vitamin D3 analogue - BioXell

Latest Information Update: 30 Dec 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer BioXell SpA; Cosmo Pharmaceuticals
  • Class Dihydroxycholecalciferols; Small molecules; Urologics; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Intercellular signalling peptide and protein inhibitors; Interleukin 8 inhibitors; Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Male infertility
  • Discontinued Benign prostatic hyperplasia; Interstitial cystitis; Overactive bladder; Prostatitis

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 08 Apr 2009 Top-line efficacy data from a Phase-IIb trial in Overactive bladder released by BioXell SpA
  • 17 Dec 2008 BioXell SpA completes enrolment in its Phase-IIb trial for Overactive bladder in the EU and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top